It has been shown to inhibit the USP1/UAF1 complex and exhibit strong dose-dependent tumor response in xenograft-derived BRCA-mutated triple-negative breast cancer with synergy seen when given with a PARP inhibitor. This evidence concerns the gene USP1 and neoplasm.